Everyone has BRCA 1 and BRCA 2 genes, they play an important role in cancer prevention. When these genes have a change or ‘alteration’, they become less able to help prevent cancer. People with a BRCA 1 or BRCA 2 gene alteration have a higher lifetime risk of certain cancers- breast, ovarian, prostate and pancreatic cancer.
Knowing you have a BRCA gene alteration offers some opportunities to reduce your risk of cancer, but it means women are faced with difficult decisions to make. To reduce the risk of breast and ovarian cancer, women have the opportunity to have a double mastectomy to remove the breasts and/or a salpingo-oophorectomy to remove the ovaries.
Those who do have risk-reducing surgery to remove their ovaries will go into a surgical menopause. This menopause is sudden and often has more severe symptoms than natural menopause.
We have funded four new early-stage studies with our small grants programmes to help improve the options, information, support for women and people with gynae organs with BRCA gene alterations.
Dr Dan Reisel and his team at UCL are developing a digital tool to help people with a BRCA gene alteration understand their options and make decisions about their health.
Dr Dan Reisel’s recent survey found that most people knew very little about BRCA alterations before their own diagnosis, and struggled to find clear, reliable and relevant information. Many turned to internet searches and online forums which may be inaccurate.
Dr Dan’s decision tool, called BRCANavigate, will be made with people with BRCA alterations and medical professionals to help ensure it is accurate and easy to use. The team hope the tool will help people understand their options and feel confident in their decisions about reducing or monitoring their risk of cancer.
Dr Zachary Nash and his team at the Institute for Women’s Health at University College London (UCL) are running a feasibility study to predict which women will experience persistent menopausal symptoms.
For most women, the symptoms of surgical menopause can be managed with hormone replacement therapy (HRT), but around 1 in 2 will have persistent menopausal symptoms that have a significant impact on their quality of life, like hot flushes, difficulty sleeping, anxiety, or memory problems (‘brain fog’). The worry of menopausal symptoms and long-term effects can create a barrier to women going for the surgery, leaving them at a higher risk of ovarian cancer.
The team will recruit 30 participants who will be put in a temporary menopause for three months, using medication that is commonly used to treat conditions like endometriosis. The participants will be given HRT and asked to record their symptoms. This first small-scale project will help the team know if this area is worth further research and give them the initial data they need to go for larger pots of funding.
Mr Hasan Mirza and his team at Imperial College London are investigating genetic patterns in precancerous lesions that could help identify who is most likely to develop ovarian cancer.
Sometimes during risk-reducing surgery precancerous lesions called serous tubal intraepithelial carcinoma are found. Having precancerous lesions does not mean you will get ovarian cancer, but they are the first step in cancer developing.
Hasan’s study aims to find genetic patterns in these precancerous changes that could help identify those most likely to develop into cancer. The team will compare the genetic profiles of women with these precancerous changes with those diagnosed with ovarian cancer. They will also look at rare cases where women with precancerous changes later developed cancer, and whether they can find any DNA markers that are linked to women having poorer outcomes.
Jemma Longley and her team at the University of Southampton are testing whether early signs of ovarian cancer can be picked up in vaginal fluid.
Jemma and her team will gather samples from women who are undergoing risk reducing surgery, including a blood test, vaginal swabs/diagnostic tampon, urine, as well as a sample of their fallopian tubes. The team will compare the samples from women with early-stage ovarian cancer to those without cancer. They will look for changes to specific markers called microRNAs in vaginal fluid and ovarian cancer cells.
The team hopes to find early markers of ovarian cancer which are also in vaginal fluid that can be used to develop a test to detect early-stage ovarian cancer. If this research is a success, the test could help women with BRCA gene alterations make informed and personalised decisions about when to have preventative surgery, or to pick up cancer early for those who are delaying or decided against surgery.
We would like to thank all of our supporters who have helped make these research projects possible.
More information
We have lots more information on our current research projects, BRCA. You can also speak to our Ask Eve nurses for free to chat about any worries or questions.